Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
- 浏览3
Clinical infectious diseases
442-452页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



